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Objectives This study was designed to evaluate myocardial substrate and high-energy phosphate (HEP) metabolism in
asymptomatic men with well-controlled, uncomplicated type 2 diabetes with verified absence of cardiac ische-
mia, and age-matched control subjects, and to assess the association with myocardial function.
Background Metabolic abnormalities, particularly an excessive exposure of the heart to circulating nonesterified fatty acids
and myocardial insulin resistance are considered important contributors to diabetic cardiomyopathy in animal
models of diabetes. The existence of myocardial metabolic derangements in uncomplicated human type 2 dia-
betes and their possible contribution to myocardial dysfunction still remain undetermined.
Methods In 78 insulin-naive type 2 diabetes men (age 56.5  5.6 years, body mass index 28.7  3.5 kg/m2, glycosy-
lated hemoglobin A1c 7.1  1.0%; expressed as mean  SD) without cardiac ischemia and 24 normoglycemic
control subjects (age 54.5  7.1 years, body mass index 27.0  2.5 kg/m2, glycosylated hemoglobin A1c 5.3 
0.2%), we assessed myocardial left ventricular (LV) function by magnetic resonance imaging, and myocardial
perfusion and substrate metabolism by positron emission tomography using H2
15O, carbon 11C-palmitate, and
18-fluorodeoxyglucose 2-fluoro-2-deoxy-D-glucose. Cardiac HEP metabolism was assessed by phosphorous P 31
magnetic resonance spectroscopy.
Results In patients, compared with control subjects, LV diastolic function (E/A ratio: 1.04  0.25 vs. 1.26  0.36,
p  0.003) and myocardial glucose uptake (260  128 nmol/ml/min vs. 348  154 nmol/ml/min, p 
0.015) were decreased, whereas myocardial nonesterified fatty acid uptake (88  31 nmol/ml/min vs.
68  18 nmol/ml/min, p  0.021) and oxidation (85  30 nmol/ml/min vs. 63  19 nmol/ml/min, p 
0.007) were increased. There were no differences in myocardial HEP metabolism or perfusion. No associa-
tion was found between LV diastolic function and cardiac substrate or HEP metabolism.
Conclusions Patients versus control subjects showed impaired LV diastolic function and altered myocardial substrate metab-
olism, but unchanged HEP metabolism. We found no direct relation between cardiac diastolic function and pa-
rameters of myocardial metabolism. (J Am Coll Cardiol 2009;54:1524–32) © 2009 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.074Lilly, GlaxoSmithKline, Merck, Novartis, and Novo Nordisk. Dr. Heine is
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October 13, 2009:1524–32 Cardiac Metabolism in Diabetic Cardiomyopathyltered cardiac function, structure, and dimensions are
ommon findings in asymptomatic patients with type 2
iabetes mellitus (T2DM), even in the absence of hyper-
ension and coronary artery disease (CAD). These alter-
tions are attributed to diabetic cardiomyopathy (DCM) (1).
iabetic cardiomyopathy is a multifactorial disease entity that
s clinically characterized by an initial increase in left ventricular
LV) stiffness (2) and subclinical diastolic dysfunction. How-
ver, DCM may advance to compromised LV systolic func-
ion, with a high propensity to progress into overt congestive
eart failure (3).
In animal models of diabetes, cardiac dysfunction coexists
ith increased myocardial nonesterified fatty acid (NEFA)
tilization, triglyceride accumulation, and subsequent in-
reased production of toxic intermediates, which, in the
resence of hyperglycemia, contribute to increased forma-
ion of reactive oxygen species, mitochondrial uncoupling,
ecreased adenosine triphosphate (ATP) synthesis, mito-
hondrial dysfunction, and finally apoptosis (1,4). These
eleterious processes are commonly referred to as
luco-lipotoxicity.
In patients with T2DM, it is technically challenging to
emonstrate the existence of these abnormalities as causal
echanisms underlying DCM. Only a few studies have
nvestigated myocardial glucose and NEFA metabolism in
he human (pre-)diabetic heart, yielding conflicting results
1,5–14). Even fewer studies related altered cardiac sub-
trate metabolism to function (8,9); however, these results
re not unequivocal. Previously, we and others (15,16)
howed decreased cardiac phosphocreatine (PCr)/ATP ra-
ios in patients with T2DM, which was associated with
iastolic dysfunction only in our study. Consequently, the
nter-relation between myocardial substrate and energy
etabolism and LV function is currently unclear in human
2DM.
The present study aimed to investigate the influence of
2DM on myocardial substrate and high-energy phos-
hate (HEP) metabolism and their relation to myocar-
ial function using cardiac magnetic resonance (CMR),
hosphorus-31 magnetic resonance spectroscopy ([31P]-
RS), and positron emission tomography (PET) in asymp-
omatic patients with recently diagnosed, uncomplicated
2DM. As CAD and ischemia influence myocardial sub-
trate preference (9,17), only T2DM patients with verified
bsence of inducible ischemia as assessed by dobutamine
tress echocardiography were included.
ethods
atients. Patients and healthy control subjects were re-
ruited by advertisements in local newspapers. Men with
ncomplicated T2DM, age 45 to 65 years, were eligible.
nclusion criteria were a glycosylated hemoglobin A1c
HbA1c) level of 6.5% to 8.5% at screening, body mass index
BMI) of 25 to 32 kg/m2, and blood pressure not exceeding
50/85 mm Hg (with or without the use of antihyperten- Fives). Patients were excluded
hen any history or complaints
elated to cardiovascular disease,
iabetes, or any clinically notice-
ble disorder was present. Pa-
ients were also excluded if they
sed thiazolidinediones, fibrates,
nsulin, or other hormonal re-
lacement therapy. Patients were
creened at 2 separate occasions.
general screening was per-
ormed, consisting of a medical
istory, physical examination,
chocardiogram, Ewing tests to
xclude cardiac autonomic neu-
opathy, and fasting blood and
rine analyses. When patients
ulfilled the initial criteria, they
nderwent a dobutamine-stress
chocardiography to exclude the
resence of cardiac ischemia or
rrhythmias at a separate visit.
ollowing successful screening,
articipants entered a 10-week
un-in period, during which their
egular blood glucose lowering
gents were transferred to
limepiride monotherapy and ti-
rated until a stable dose was
eached during 8 weeks prior to
ssessments to exclude possible
onfounding effects on myocar-
ial metabolism of differential
gents. Mean HbA1c levels at
creening and at the end of the
un-in period were comparable
data not shown).
Healthy men, age 45 to 65
ears, with normal glucose me-
abolism, as assessed by a 75-g
ral glucose tolerance test, were eligible as control subjects.
nclusion criteria were a BMI of 25 to 32 kg/m2 and blood
ressure 150/85 mm Hg. Exclusion criteria were a history
f or current cardiovascular disease, dyslipidemia, and the
se of any prescribed medication. Control subjects under-
ent the same first screening visit as patients. CAD in
ontrol subjects was considered to be absent when there
ere no cardiac problems at rest and during exercise and
hen a normal electrocardiogram was present. The study
as performed at 2 sites (Amsterdam and Leiden, the
etherlands). The protocol was approved by the Medical
thics Committee of both centers and performed in full
ompliance with the Declaration of Helsinki.
iochemical analyses. HbA1c was determined by high-
erformance liquid chromatography (Menarini Diagnostics,
Abbreviations
and Acronyms
ATP  adenosine
triphosphate
BMI  body mass index
CAD  coronary artery
disease
CMR  cardiac magnetic
resonance
DCM  diabetic
cardiomyopathy
18FDG  18-
fluorodeoxyglucose
2-fluoro-2-deoxy-D-glucose
HbA1c  glycosylated
hemoglobin A1c
HEP  high-energy
phosphate
LV  left ventricular
LVM  left ventricular
mass
MFAE  myocardial fatty
acid esterification
MFAO  myocardial fatty
acid oxidation
MFAU  myocardial fatty
acid uptake
MMRglu  myocardial
metabolic rate of glucose
uptake
NEFA  nonesterified fatty
acid
PCr  phosphocreatine
PET  positron emission
tomography
[31P]-MRS  phosphorus-
31 magnetic resonance
spectroscopy
T2DM  type 2 diabetes
mellituslorence, Italy), with reference values of 4.3% to 6.1%.
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Cardiac Metabolism in Diabetic Cardiomyopathy October 13, 2009:1524–32-terminal pro–B-type natriuretic peptide was measured
sing an electrochemiluminescence immunoassay (Roche
iagnostics GmbH, Mannheim, Germany). The intra-
ssay coefficient of variation was 1.5%, and the interassay
oefficient of variation was 1.9%. The lower detection limit
as 5 ng/l. The plasma concentration of malondialdehyde
as determined in duplicate by high-performance liquid
hromatography after alkaline hydrolysis and reaction with
hiobarbituric acid (18). The intra-assay coefficient of vari-
tion was 5.7%. Ultra-sensitive C-reactive protein was
etermined by ELISA (DSL, Webster, Texas).
maging. The study protocol was performed on 2 different
ccasions, separated by 2 days, and consisted of CMR and
31P]-MRS on the first and PET on the second occasion or
ice versa. All participants underwent CMR measurements.
ue to the demanding protocol, [31P]-MRS was offered as
n optional test. The PET measurements were performed in
he first 60 patients entering the study. The patients did not
ake glucose lowering medication in the morning prior to
ssessments.
MR imaging protocol. The CMR assessments were
erformed after an overnight fast at a single center (Leiden),
sing a 1.5-T whole-body MR scanner (Gyroscan ACS/
T15, Philips, Best, the Netherlands). During CMR ex-
minations, blood pressure and heart rate were monitored
nd blood samples were collected to determine substrates.
ate pressure product was calculated as the product of
ystolic blood pressure and heart rate. The entire heart was
maged in the short-axis orientation using electrocardio-
raphically gated breath-hold balanced steady-state free
rocession imaging (19).
Measures of systolic function were LV ejection fraction,
ardiac work, and cardiac index (cardiac output/body surface
rea). The cardiac dimensions were LV end-diastolic vol-
me index, LV end-systolic volume, LV stroke volume, and
eft ventricular mass (LVM) index (I). An electrocardio-
raphically gated gradient-echo sequence with velocity en-
oding was performed to measure blood flow across the
itral valve for the determination of LV diastolic function
arameters, including peak filling rates of the early filling
hase (E) and the atrial contraction (A). The E/A ratio was
alculated. Additionally, the peak deceleration of E (E-
ecpeak) was calculated (19). The LV filling pressures (E/Ea)
ere estimated (20). Images were analyzed quantitatively
sing dedicated software (MASS and FLOW, Medis,
eiden, the Netherlands).
hosphorus magnetic resonance spectroscopy. A 100-
m-diameter surface coil was used to acquire electrographi-
ally triggered [31P]-MR spectra of the LV anterior wall
ith subjects in the supine position. Volumes of interest
ere selected by image-guided spectroscopy with
-dimensional image selected in vivo spectroscopy. Shim-
ing was performed automatically and tuning and match-
ng of the 31P surface coil was performed manually. Tech-
ical details of data acquisition and spectral quantification
ere similar as described elsewhere (21). Briefly, spectro- scopic volume size was typically 7 7 7 cm. Acquisitions
ere based on 192 averaged free-induction decays, and total
cquisition time was 10 min. The [31P]-MR spectra were
uantified automatically in the time domain using prior
pectroscopic knowledge and were corrected for partial
aturation effects and for the ATP contribution from blood
n the cardiac chambers. The PCr/ATP ratios of the spectra
ere calculated and used as a parameter representing myo-
ardial HEP metabolism (22).
ET imaging protocol. The PET examinations were per-
ormed after an overnight fast at a single center (Amster-
am) using an ECAT EXACT HR scanner (Siemens/
TI, Knoxville, Tennessee). Patients received 2 venous
atheters: 1 in an antecubital vein and 1 in the vein of the
pposite hand, with the latter being wrapped into a heated
lanket to obtain arterialized blood. During procedures,
atients were monitored by telemetry, and blood pressure
as measured at 5-min intervals. Positron emission tomog-
aphy was used to measure myocardial blood flow with
2
15O, myocardial NEFA uptake (MFAU), beta-oxidation
MFAO), and esterification (MFAE) with carbon 11C-
almitate, and myocardial metabolic rate of glucose uptake
MMRglu) with 18-fluorodeoxyglucose-2-fluoro-2-deoxy-
-glucose (18FDG). Perfusion and NEFA metabolism
ere assessed in the fasting state, whereas MMRglu was
easured during euglycemic-hyperinsulinemic clamp pro-
edure. Following a 10-min transmission scan for attenua-
ion correction, H2
15O was injected (t  10 min), and a
0-min dynamic emission scan (40 frames with increasing
rame length) was acquired. Subsequently, a 30-min dy-
amic emission scan (34 frames) was performed following
1C-palmitate injection (t  35 min). Hereafter, the clamp
as started (t  65 min), as described elsewhere (23), to
pproximate an isometabolic steady state (plasma glucose
evel 5 mmol/l) and measure whole-body insulin sensitivity.
t steady state (around t  155 min), following a new
ransmission scan, 18FDG was injected, and a 60-min
ynamic emission scan (40 frames) was acquired. Blood
amples were collected during 11C-palmitate and 18FDG
cans at pre-defined time points to measure glucose, NEFA,
actate, lipids, and insulin levels. In addition, 11CO2 was
easured during the 11C-palmitate scan (14). Total radia-
ion exposure was 4.87 mSv.
ET image analysis. The PET data were quantitatively
econstructed using filtered backprojection applying all ap-
ropriate corrections. To generate myocardial time-activity
urves, regions of interest were defined on resliced LV
hort-axis (summed) 11C-palmitate and 18FDG images and
ubsequently projected onto the dynamic images. The
egions of interest were drawn as previously described (24)
nd grouped for further analysis. Myocardial segments
xposed to liver spill-in were omitted from the analysis of
1C-palmitate data. Additional regions of interest were
efined in left and right ventricular chambers for 11C-
almitate and H2
15O image-derived input functions. A
eparate aorta ascendance region of interest was defined for
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October 13, 2009:1524–32 Cardiac Metabolism in Diabetic Cardiomyopathyhe 18FDG image-derived input function. Myocardial blood
ow was determined using the standard single-tissue com-
artment model (25). The 11C-palmitate time-activity
urves were analyzed using a 3-tissue plasma input kinetic
odel, which, together with plasma NEFA concentrations,
nabled calculation of MFAU, MFAO, and MFAE (26).
he 11C-palmitate image-derived input function was cor-
ected for 11CO2 metabolites and difference between plasma
nd whole blood concentrations as described elsewhere (14).
his model is similar to that described by Bergmann et al.
27), but with a reduced number of free parameters, thereby
ncreasing precision of derived estimates (Online Fig. 1).
hen, MMRglu was calculated by multiplying the net influx
onstant for 18FDG, Ki, by the mean plasma glucose
oncentration. For determination of Ki, Patlak graphical
nalysis was used (28).
tatistical analysis. Values are expressed as mean  SD or
edian (interquartile range). Non-normally distributed data
ere logarithmically transformed. Comparisons between
atients and control subjects were made using the
ndependent-sample t test.
Linear regression was used to adjust for BMI differences
etween groups. Univariate and multiple analyses with a
orward selection procedure were performed. The goal of
hese analyses was to determine which factors were respon-
ible for the difference in LV diastolic function (E/A and
-decpeak) between groups. We employed a 2-step strategy
or the selection of variables. The first step was that a
ariable had to be significantly different between groups. If
o, in univariate analysis there had to be an association
etween this variable and the dependent variable with p 
.1. The variables fulfilling these criteria were then entered
n a forward multivariable regression analysis, and those
ith p  0.05 were considered independently related to the
ependent variable. Analyses were performed with SPSS
oftware version 15.0 (SPSS Inc., Chicago, Illinois). A
-tailed probability value 0.05 was considered significant.
esults
ubject characteristics, hemodynamics, and LV dimen-
ions and function. A total of 173 patients underwent the
eneral screening; 96 patients fulfilled all inclusion criteria.
herefore, 96 patients underwent dobutamine-stress echocar-
iography. Sixteen patients were excluded (17.7%) as result of
positive test, and 2 patients withdrew before measurements,
eaving a total of 78 patients entered into the study.
Patients and control subjects were similar with respect to
ge, but patients had a slightly higher BMI and waist
ircumference (Table 1). The lipids profiles were different
etween patients and control subjects (Table 1). Table 2
hows hemodynamic and cardiac parameters. Blood pres-
ures and heart rates were within the normal range, but
lightly higher in patients than in control subjects. Patients
ad a significantly lower LV end-diastolic volume (index) gnd LV stroke volume than control subjects in the presence
f comparable LVM index, LV ejection fraction, cardiac
ndex, and cardiac work. Patients had significantly decreased
iastolic functional parameters. Mean E/Ea and N-terminal
ro–B-type natriuretic peptide, both estimates of LV filling
ressure, were not different between both groups. In T2DM
atients, the relation between LV end-diastolic volume
index) and E/Ea was shifted toward decreased compliance
Fig. 1).
yocardial substrate and HEP metabolism. All 18FDG
nd all but 1 of the H2
15O scans were appropriate for analysis.
ue to technical difficulties, 11C-palmitate images from 8
atients and 4 control subjects were not available for
nalysis. Due to the demanding protocol or insufficient
pectral quality (Cramér-Rao standard deviation 20%)
21), [31P]-MRS data were available for analysis in 35
atients and 19 control subjects.
Table 3 lists the fasting biochemical variables obtained
efore the onset of H2
15O and 11C-palmitate PET and
uring euglycemic hyperinsulinemia (i.e., during 18FDG-
ET). Myocardial blood flow was similar between patients
nd control subjects (0.884  0.213 g/ml/min vs. 0.894 
.215 g/ml/min, p  0.804). In patients, MFAU (88  31
mol/ml/min vs. 68  18 nmol/ml/min, p  0.021) and
FAO (85  30 nmol/ml/min vs. 63  19 nmol/ml/min,
 0.007) were higher than in control subjects, whereas the
egligible MFAE was lower in patients versus control
ubjects (2.3  4.5 nmol/ml/min vs. 5.3  5.4 nmol/ml/
in, p  0.028) (Fig. 2A). Myocardial metabolic rate of
ubject CharacteristicsTable 1 Subject Characteristics
Control Subjects
(n  24)
Type 2 Diabetic
Patients
(n  78)
Age, yrs 54.5 7.1 56.5 5.6
Time since diagnosis of diabetes, yrs NA 4 (2–6)
Current smoker, n/N 0/24 17/78*
Body mass index, kg/m2 27.0 2.5 28.7 3.5†
Waist circumference, cm 99 9 104 10‡
HbA1c, % 5.3 0.2 7.1 1.0*
Total cholesterol, mmol/l 5.3 0.7 4.7 1.0†
LDL cholesterol, mmol/l 3.4 0.65 2.7 0.78*
HDL cholesterol, mmol/l 1.4 (1.3–1.6) 1.1 (0.9–1.3)*
Triglycerides, mmol/l 0.9 (0.7–1.1) 1.5 (1.0–2.2)*
Medications, % (n/N)
Statins NA 49 (38/78)
Any antihypertensive medication NA 44 (34/78)
Beta-blockers NA 9 (7/78)
Diuretics NA 15 (12/78)
ACE inhibitors NA 23 (18/78)
Angiotensin II blocker NA 12 (9/78)
Calcium antagonists NA 5 (4/78)
ata are mean SD or median (interquartile range). *p  0.001, †p  0.01, ‡p  0.05.
ACE  angiotensin-converting enzyme; HbA1c  glycosylated hemoglobin A1c; HDL  high-
ensity lipoprotein; LDL  low-density lipoprotein; NA  not applicable.lucose intake was lower in patients than in control subjects
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Cardiac Metabolism in Diabetic Cardiomyopathy October 13, 2009:1524–32260 128 nmol/ml/min vs. 348 154 nmol/ml/min, p
.015) (Fig. 2B). Following correction for BMI differences
etween groups, only the difference in MFAE was no longer
tatistically significant. Analysis of T2DM patients and
ontrol subjects in whom the PCr/ATP ratio was available
id not reach significance: MFAU (76  24 nmol/ml/min
s. 68  19 nmol/ml/min, p  0.303), MFAO (74  23
mol/ml/min vs. 63  19 nmol/ml/min, p  0.127),
nd MMRglu (284  149 nmol/ml/min vs. 363  161
ol/ml/min, p  0.116). Moreover, the PCr/ATP ratio
as comparable in the 2 groups (2.09  0.33 vs. 2.12 
.32, p  0.817) (Fig. 2C).
orrelations and determinants of LV diastolic function.
hole-body insulin sensitivity and cardiac substrate or
EP metabolism were not directly associated with LV
unction. In pooled analysis, the value for the whole body
nsulin sensitivity adjusted during the steady state was
ositively correlated with MMRglu (r  0.452, p  0.001),
hereas an inverse correlation was found with NEFA (r 
0.361, p  0.001), MFAU (r  –0.255, p  0.042), and
FAO (r  –0.288, p  0.021). We found NEFA was
egatively associated with MMRglu (r  –0.562, p 
.001). Forward multiple regression analysis revealed heart
ate, HbA1c, and diastolic blood pressure as independent
eterminants of E/A ratio (R2  0.29, p  0.001) and
emodynamic Parameters, Cardiacimensions, and Func ion in the Study PopulationTable 2 Hemodynamic Parameters, Cardi cDimensions, and Function in the Study Population
Control Subjects
(n  24)
Type 2 Diabetic
Patients
(n  78)
Hemodynamics
Systolic blood pressure, mm Hg 118 11 128 12*
Diastolic blood pressure, mm Hg 72 8 76 7‡
Heart rate, beats/min 56 (51–62) 64 (60–70)*
Rate pressure product,
beats/min·mm Hg
6,684 1,441 8,345 1,457*
Systolic function and dimensions
LV mass, g 111 24 107 17
LV mass index, g·m2 51 (47–60) 50 (46–55)
LV end-systolic volume, ml 72 (63–82) 59 (52–71)†
LV stroke volume, ml 107 23 94 16†
Ejection fraction, % 59 4 60 6
Cardiac index, l/min·m2 2.9 (2.6–2.9) 2.8 (2.6–3.2)
Cardiac work,
mm Hg·ml1·min1
51.7 10.9 56.5 11.8
Diastolic function and dimensions
LV end-diastolic volume, ml 181 36 156 25*
LV end-diastolic volume index,
ml·m2
87 14 74 11*
E peak filling rate, ml/s 503 112 417 84†
E deceleration peak, ml/s2·103 4.73 (3.11–5.19) 3.40 (2.89–3.99)†
E/A ratio 1.26 0.36 1.04 0.25‡
E/Ea 8.8 3.0 10.0 4.3
ata are mean  SD or median (interquartile range). *p  0.001, †p  0.01, ‡p  0.05.
A  diastolic atrial contraction; E  early diastolic filling phase; E/Ea  estimate of the left
entricular filling pressure; LV  left ventricular.-decpeak (R
2  0.27, p  0.001) (Table 4).iscussion
his study is novel in several ways. To our knowledge, this
s: 1) the largest group of well-characterized male T2DM
atients with 2) verified absence of (inducible) cardiac
schemia who had extensive evaluation of 3) combined
ardiac substrate and HEP metabolism as well as function
ith CMR and PET technology under standardized con-
itions. In addition, 4) this study is the first to show
onvincingly an increase in myocardial fatty acid metabo-
ism in T2DM patients, whereas 5) no direct relation was
ound between cardiac diastolic function and parameters of
yocardial substrate or energy metabolism.
yocardial function. The findings of the present study are
n line with previous reports, showing LV diastolic dysfunc-
ion in asymptomatic patients with T2DM (15). The
trength of the present study is the a priori exclusion of
articipants with inducible ischemia, as ischemia is a critical
eterminant of both cardiac function and substrate and
nergy metabolism (9,17). Previous studies evaluating LV
unction and dimensions in human diabetes have mainly
sed echocardiography, which is hampered by several well-
nown limitations, particularly in overweight/obese popu-
ations (29). We used CMR, which represents the gold
tandard for reproducible, observer-independent quantita-
ive assessment of LV volume and mass and has been shown
o be an important tool for the assessment of diastolic and
ystolic function together with excellent accuracy and repro-
ucibility (29). The observed LV diastolic dysfunction and
ecreased LV volumes, in the presence of normal LVM,
ystolic function, and cardiac work, unveil early abnormal-
ties in LV function and compliance in the course of DCM.
hus, the functional changes cannot be explained by in-
Figure 1 Relation of LVEDVI and the
Estimate of LV Filling Pressure E/Ea
Relation between left ventricular end-diastolic volume index (LVEDVI) and the
estimate of left ventricular (LV) filling pressure E/Ea in control subjects (open
box, n  24) and type 2 diabetes mellitus (T2DM) patients (solid box, n 
78). Values are mean  SD. The LVEDVI was significantly lower in type 2 dia-
betes mellitus patients (p  0.001) at similar estimates of LV filling pressure
(E/Ea, p  0.228) compatible with decreased LV compliance in T2DM patients.
c
L
m
M
m
d
(
p
a
f
v
i
r
p
i
D
c
p
I
p
(
w
p
t
N
h
r
r
m
(
m
r
t
F
n
e
m
N
h
a
c
o
N
m
1
o
BC
D
N
1529JACC Vol. 54, No. 16, 2009 Rijzewijk et al.
October 13, 2009:1524–32 Cardiac Metabolism in Diabetic Cardiomyopathyreased LVM, even after adjustment for BMI, or by raised
V pressure because the estimates of LV filling pressure
easured were similar in both groups.
yocardial substrate metabolism. Myocardial substrate
etabolism was previously studied in humans with various
egrees of glucometabolic abnormalities and comorbidities
5–14). These small-sized studies used PET or single-
hoton emission computed tomography to assess glucose
nd NEFA metabolism, applying several tracers with dif-
erent isotopes and metabolic fates, but they also used
arious approaches to data analysis. Due to these differences
n populations and methodology, different, often conflicting
esults were obtained (5–8,14). In the present study, T2DM
atients had increased NEFA uptake and oxidation, which
s compatible with the data derived from animal models of
CM (1,30). Increased myocyte NEFA metabolism can be
aused by elevated plasma NEFA supply due to unsup-
ressed lipolysis from insulin-resistant adipocytes (31,32).
nterestingly, similar to findings by others in comparable
opulations (9–11), but in contrast to most animal studies
30), fasting plasma NEFA levels in our T2DM patients
ere similar to control subjects. In addition, myocardial
erfusion was comparable between both study groups; thus,
hese factors do not explain the observed increases in cardiac
EFA metabolism. Increased NEFA metabolism can,
owever, be explained by alterations at a cellular level. In
ats fed a high-fat diet, the fatty acid transporter CD36 was
elocated to the sarcolemma, and basal phosphorylation of a
ediator of CD36, that is, protein kinase B, was increased
33). In addition, in Zucker diabetic fatty rats, increased
yocardial NEFA use was found, and this was shown to be
elated to increased peroxisome proliferator-activated recep-
or alpha and/or its coactivator PGC-1 activation (34,35).
inally, in ZDF rats, we found increased messenger ribo-
iochemical and Metabolicharacteristics of the Study PopulationTable 3 Biochemical and MetabolicCharacteristics of the Study Population
Control Subjects
Type 2 Diabetic
Patients
Fasting n  24 n  78
Plasma glucose, mmol/l 5.3 (5.0–5.6) 8.3 (7.1–10.0)*
Plasma nonesterified fatty acids,
mmol/l
0.46 (0.37–0.52) 0.50 (0.40–0.62)
Plasma insulin, pmol/l 28 (19–33) 64 (36–92)*
Plasma lactate, mmol/l 0.8 (0.7–0.9) 1.2 (1.0–1.5)*
NT-proBNP, ng/l 28 (21–76) 27 (20–42)
usCRP, mg/l 3.0 (1.7–6.4) 3.8 (2.4–6.1)
Malondialdehyde, mol/l 6.1 0.7 9.8 2.3*
During hyperinsulinemia n  19 n  72
Plasma nonesterified fatty acids,
mmol/l
0.04 (0.02–0.05) 0.08 (0.05–0.16)*
Plasma insulin, pmol/l 513 64 583 143
Plasma lactate, mmol/l 1.1 (0.9–1.3) 1.1 (1.0–1.3)
M/I value, (mg/kg · min)/(pmol/l) 0.99 (0.72–1.65) 0.46 (0.24–0.74)*
ata are mean  SD or median (interquartile range). *p  0.001.
M/I value  whole body insulin sensitivity adjusted during the steady state; NT-proBNP 
-terminal pro–B-type natriuretic peptide; usCRP  ultrasensitive C-reactive protein.ucleic acid levels of the mitochondrial NEFA shuttlingnzyme carnitine palmitoyltransferase, which subsequently
ay lead to enhanced NEFA oxidation (33). Furthermore,
EFA levels under hyperinsulinemia were significantly
igher in patients than in control subjects and were inversely
ssociated with whole-body insulin sensitivity and the myo-
ardial metabolic rate of glucose uptake, confirming previ-
us findings (9,12,13). Theoretically, increased cardiac
EFA metabolism should be paralleled by a decrease in
yocardial glucose uptake, measured as insulin-stimulated
8FDG uptake. However, studies in T2DM subjects with-
ut CAD have reported both decreased (9,11–13) and
Figure 2 Myocardial Substrate and
High-Energy Phosphate Metabolism
Myocardial fatty acid uptake (MFAU), myocardial fatty acid oxidation (MFAO),
and myocardial fatty acid esterification (MFAE) (A); the metabolic rate of glu-
cose uptake (MMRglu) (B); and phosphocreatine/adenosine triphosphate
(PCr/ATP) ratio (C) in control subjects (open bars) and T2DM patients (solid
bars). *p  0.001, †p  0.01, ‡p  0.05. Abbreviation as in Figure 1.
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Cardiac Metabolism in Diabetic Cardiomyopathy October 13, 2009:1524–32naltered (10) cardiac glucose uptake. Again, differences in
opulation characteristics and methodological issues pre-
lude comparison of these studies. We found decreased
lucose uptake, which is compatible with NEFA substrate
ompetition, decreased myocardial insulin signaling (32),
nd/or reduced membrane-bound GLUT4 (35). Alto-
ether, these findings implicate that the nonischemic myo-
ardium in uncomplicated T2DM is resistant to insulin-
ediated glucose uptake and that cardiac NEFA metabolism
s augmented.
yocardial substrate and HEP metabolism in relation to
unction. Studies aimed at linking cardiac substrate and
EP metabolism and function in humans with glucometa-
olic disorders are largely lacking. Using iodine (I) 123
eptadecanoic acid single-photon emission computed to-
ography, Turpeinen et al. (8) reported decreased myocar-
ial NEFA uptake and kinetics in subjects with impaired
lucose tolerance and T2DM, relative to type 1 diabetes
ellitus patients and control subjects, which was associated
ith LVM measured by ultrasound. There were no func-
ional differences between the groups, and no correlation
as reported between functional measurements and [123I]-
eptadecanoic acid metabolism. Iozzo et al. (9) reported a
eak correlation (r  0.38, p  0.02) between insulin-
timulated myocardial glucose uptake and ejection fraction
n a pooled analysis of control subjects, patients with type 1
iabetes mellitus, CAD patients without T2DM, and pa-
ients with T2DM without CAD. These investigators
uggested that the impairment of myocardial glucose uptake
s such might compromise myocardial function. In their
ombined group of subjects of various age groups, the
jection fraction varied substantially, with approximately
0% of participants having an ejection fraction 40% with
xtreme values as low as 10% (9). In our study, the ejection
raction in T2DM subjects and control subjects was similar,
ith small standard deviations in both groups, which may
ave precluded the detection of an association of LV
unction and myocardial glucose uptake. The inter-relation
f altered myocardial substrate handling, HEP metabolism,
nivariable and Multivariable Linear Regression Analysis ofiastolic Function Me surements E/A Ratio a d E Deceleration PeTable 4 Un variable and Multivariable Linear Regressi n AnalysDiastolic Function Measurements E/A Ratio and E Dec
E/A Ratio
Univariable
Beta p Value
Systolic blood pressure, mm Hg 0.008 0.001
Diastolic blood pressure, mm Hg 0.015 0.001 
Heart rate, beats/min 0.012 0.001 
HbA1c, % 0.091 0.001 
Plasma glucose, mmol/l 0.340 0.007
Plasma lactate, mmol/l 0.095 0.037
Plasma nonesterified fatty acids, mmol/l 0.277 0.059
Diabetic status 0.211 0.002
bA1c  glycosylated hemoglobin A1c; other abbreviations as in Table 2.nd LV function is complex and depends on many factors, including additional comorbidities, such as hypertension
nd cardiac autonomic neuropathy, and the presence or
bsence of stress or ischemia.
Previously, we and others (15,16) reported decreased
yocardial PCr/ATP ratio in T2DM patients relative to
ontrol subjects. In the present study, we could not confirm
hese previous findings. Several differences in patient char-
cteristics between the present and the 2 other studies, such
s age range (36), BMI differences (37), inclusion of only
en or both sexes (38), glycemic control, and fasting NEFA
evels, may have led to these discrepant findings. Because
ltered myocardial substrate metabolism may affect cardiac
Cr/ATP (39), we argue that the insufficient contrast
etween the present subgroups regarding cardiac substrate
etabolism may have potentially contributed to the finding
f comparable myocardial PCr/ATP values in both groups.
In our previous study (15), a relation was found between
yocardial LV diastolic function and cardiac PCr/ATP.
his relation was not found by Scheuermann-Freestone
t al. (16), who found a similar LV diastolic function in
2DM patients and control subjects. Likewise, we did not
nd a relation between LV diastolic function and cardiac
Cr/ATP in the present study. Again, the lack of contrasts
etween T2DM patients and control subjects, with respect
o LV diastolic function (16) or cardiac PCr/ATP (in the
resent study), may have precluded the finding of the
reviously observed association. Interestingly, a recent study
n Zucker diabetic fatty rats showed that not myocardial
nergy metabolism per se, but rather cardiac remodeling
ffected the observed cardiac dysfunction (40).
Although we did not find a direct association between
ltered myocardial substrate metabolism and LV functional
hanges in T2DM, an indirect effect of cardiac metabolic
erangements may influence LV function. Accordingly,
ecent data indicate that diabetes-related metabolic changes
ight indirectly impair LV diastolic function by inducing
issue oxidative stress, thereby promoting apoptosis and
xidative modification of contractile proteins, and/or by
timulating cardiac macrophage infiltration leading to local
tion Peak
E Deceleration Peak
ultivariable Univariable Multivariable
p Value Beta p Value Beta p Value
— 0.028 0.003 — —
0.017 0.058 0.001 0.043 0.005
0.003 0.044 0.001 0.026 0.029
0.030 0.363 0.001 0.264 0.007
— 0.150 0.002 — —
— 0.429 0.016 — —
— — — — —
— 0.971 0.001 — —akis of
elera
M
Beta
—
0.009
0.009
0.051
—
—
—
—nflammation and fibrosis (41).
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October 13, 2009:1524–32 Cardiac Metabolism in Diabetic Cardiomyopathytudy limitations. Due to the intraindividual diurnal fluc-
uations of substrate plasma levels in T2DM, real-life
ardiac substrate metabolism may be difficult to establish.
he euglycemic-hyperinsulinemic clamp guarantees an iso-
etabolic state in experimental groups, allowing compari-
ons of cardiac glucose metabolism between groups. Inas-
uch as hyperinsulinemia will lead to direct uptake of
lasma NEFA into nonadipose tissues other than the
yocardium, NEFA metabolism was assessed in the fasting
tate and therefore does not allow the establishment of a
irect association of cardiac NEFA and glucose metabolism.
urthermore, the present study does not address myocardial
fficiency because the used tracers do not measure myocar-
ial oxygen consumption. Further studies are needed to
ettle this issue in T2DM patients. Finally, the assessment
f only men limits generalization of the findings.
onclusions
n the absence of myocardial ischemia, patients with un-
omplicated T2DM showed impaired LV diastolic function
nd decreased compliance, in addition to whole-body and
yocardial insulin resistance, collectively leading to altered
yocardial substrate metabolism, favoring NEFA over glu-
ose as a substrate. We did not find a direct relation between
ltered LV diastolic function and myocardial substrate or
EP metabolism in this early stage of nonischemic DCM.
arge-scale longitudinal studies using similar combined
easurements should establish the influence of early meta-
olic and functional changes on the development of clini-
ally relevant cardiac disease in T2DM over time, including
ongestive heart failure and cardiac ischemia, and further
efine the efficacy of targeted interventions to halt the
rogression of compensated DCM into overt cardiac
isease.
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APPENDIX
or supplementary discussions of the 11C-palmitate kinetic analysis,
ncluding Online Figure 1 and [31P]-MRS technique, please see the online
ersion of this article.
